Home » Topics » Conferences

Conferences
RSS

L-742728 selected by Merck & Co. for further evaluation

April 12, 1996

HGH delivery agents reported by Emisphere Technologies

April 5, 1996

Provir to enter phase II soon

April 5, 1996

SB-214857 in preclinical studies

April 5, 1996

New endothelin antagonists from RPR reported at 211th ACS

April 5, 1996

New agent for sudden cardiac death in phase I at Nortran

April 5, 1996

Another antioxidant from Oxis: TX-153

April 5, 1996

BXT-51072 in line for clinical evaluation at Oxis

April 5, 1996

Novel vasoprotectants in AtheroGenics' pipeline

April 5, 1996

PB-005 slated to enter phase II

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...